Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ADVENZYMES

ADVENZYMES

HealthcarePharmaceuticals & Biotechnology₹3123 cr market cap
₹296.25 ▲ +5.43% today As of 19 Nov 2026
52-week low ₹248.3552-week high ₹392.10

-28.3% from the 52-week high · +13.1% above the low

Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra and currently employs 322 full-time employees. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather and bio-fuels. Its oils and fats processing include oil extraction, oil refining fish oil processing, biodiesel and oleochemicals.

The short version. ADVENZYMES reported revenue of ₹215 crore for Sep 2026, up 16.2% from a year earlier. Net profit was ₹48 crore (up 11.6% year on year). Return on equity was 10.3% in Mar 2026. Promoter holding was 43.56% in Sep 2026, up 0.64 points over 8 quarters.

1 · The price

How has the stock traded?

ADVENZYMES trades 28.3% below its 52-week high and 13.1% above its 52-week low.

Change over period: —

1M+7.3%
3M-7.9%
6M-27.7%
1Y-15.0%

2 · The business

Is it growing?

Sales, year on year+16.2%

Sep 2026 revenue of ₹215 cr.

Profit, year on year+11.6%

Sep 2026 net profit of ₹48 cr.

Net margin22.5%

1.0 pts lower than a year earlier.

3-year growth16.9% profit

Revenue compounded at 11.3% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue215190203172185186167169
Net profit4837434243402638
Net margin %22.519.521.124.723.521.515.822.3
EPS (₹)4.353.313.843.83.873.572.373.36

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue746637624541529502444420
Net profit169131133106120146129111
Net margin %22.620.621.419.522.629.129.126.5
EPS (₹)15.0711.7211.929.4510.713.0911.589.95

3 · The quality

How well does it turn capital into profit?

Return on equity was 10.3% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %10.39.210.18.6
Return on capital %13.612.513.410.6
EBITDA margin %35.334.034.231.4
Net margin %21.619.620.218.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR11.3%8.9%
Profit CAGR16.9%2.9%
Debt to equity0.01
Interest cover89.5x
Current ratio9.78
P/E ratio18.4

4 · The owners

Who holds it, and are they adding?

Promoter holding43.56%

Up 0.64 pts over 8 quarters.

Foreign institutions26.65%

Up 14.07 pts over 8 quarters.

Domestic institutions1.89%

Down 6.29 pts over 8 quarters.

Mutual fund schemes13

+3 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter42.9243.0843.0843.0843.0443.2643.2443.56+0.64
FII12.5811.923.4625.4125.8625.4926.7126.65+14.07
DII8.188.198.456.415.515.414.781.89-6.29
Public36.3236.8325.0225.125.5925.8425.2727.9-8.42

Mutual fund holdings · Oct 2026

13 schemes hold this stock

10 the month before.

  • UTI - MNC Fund1.12% of NAV
  • Motilal Oswal Nifty Microcap 250 Index Fund0.15% of NAV
  • Motilal Oswal BSE Healthcare ETF0.08% of NAV
  • Bandhan BSE Healthcare Index Fund0.08% of NAV
  • JioBlackRock Flexi Cap Fund0.06% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.01% of NAV
  • Bandhan Nifty Total Market Index Fund0.01% of NAV
  • Mirae Asset Nifty Total Market Index Fund0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ADVENZYMES are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ADVENZYMES

What is the ADVENZYMES share price?

ADVENZYMES (ADVENZYMES) last closed at ₹296.25, up 5.43% on the day. Its 52-week range is ₹248.35 to ₹392.10.

What is the market cap of ADVENZYMES?

ADVENZYMES has a market capitalisation of about ₹3,123 crore. Its price-to-earnings ratio is 18.4.

How are ADVENZYMES's latest results?

ADVENZYMES reported revenue of ₹215 crore for Sep 2026, up 16.2% from a year earlier. Net profit was ₹48 crore (up 11.6% year on year). Return on equity was 10.3% in Mar 2026. Promoter holding was 43.56% in Sep 2026, up 0.64 points over 8 quarters.

Who owns ADVENZYMES?

As of Sep 2026, shareholding was: Promoter 43.56%, FII 26.65%, DII 1.89%, Public 27.9%.

How many mutual funds hold ADVENZYMES?

13 mutual fund schemes held ADVENZYMES in October 2026. That compares with 10 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 23 Jul 2025 · Final Dividend - Rs. 1.2
  • 16 May 2025 · Interim Dividend - Rs. 4
  • 18 Jul 2024 · Final Dividend - Rs. 1.1
  • 17 May 2024 · Interim Dividend - Rs. 4
  • 04 Aug 2023 · Final Dividend - Rs. 1
  • 19 May 2023 · Interim Dividend - Rs. 4

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.